FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206520> ?p ?o ?g. }

• W4387206520 endingPage "e127" @default.
• W4387206520 startingPage "e126" @default.
• W4387206520 abstract "Metastasis-directed radiation therapy using stereotactic body radiation therapy (SBRT) in oligometastatic prostate cancer (Oligo PCa) has a demonstrated benefit for local control and biochemical recurrence free survival for men with oligorecurrent PCa; however, the impact of SBRT within other oligometastatic states and in the context of systemic therapy remains poorly characterized. In this study, we investigate prognostic factors for clinical outcomes in a prospective cohort of Oligo PCa patients treated with metastasis-directed SBRT.Using a single-institution registry trial, we analyzed a prospective cohort of 86 patients with Oligo PCa (≤5 metastatic lesions) and treated with metastasis-directed SBRT between 2017- 2022. Patients were classified as synchronous, metachronous, or induced oligometastatic disease as per the ESTRO guidelines. We evaluated the time to radiographic progression (TTRP), defined as the time from SBRT start date to radiographic progression, as well as time to initiation of new treatment (TTNT), defined as the time from SBRT end date to initiation of new therapy (systemic or radiation therapy). Time to event (TTE) was defined as the time from SBRT start date to radiographic progression or initiation of new therapy, whichever occurred first. Patients without documented events were censored at the date of last disease assessment. Comparative analyses were performed using Kaplan-Meier and Cox proportional hazards regression methods.Eighty-six men with Oligo PCa treated with SBRT were followed for a median of 16.4 months with M0 (73%), Oligo PCa (21%) or polymetastatic PCa (6%) GS > = 8 (63%) at initial diagnosis. At the time of treatment with initial SBRT, 21% had synchronous oligometastatic disease, 63% had metachronous or repeat oligorecurrence or oligoprogression, and 16% had induced oligometastatic disease. Most patients were treated to 1-3 sites (94%), which predominantly included bone (86%), and the median dose was 35 Gy/5F. Concurrent systemic therapy during SBRT was seen in 85% of patients, including (60.5% with new generation androgen receptor signaling inhibitors). Overall survival at 1-year and 2-years was 96.9% [95% CI, 88.2-99.2%] and 94.4% [95% CI, 83.2-98.2%]. Using univariable analysis, those who did not receive systemic treatment during SBRT had significantly shorter TTRP (HR 3.67, [95% CI, 1.62-8.32], p = 0.002), TTNT (HR 3.24, 95% CI [1.49-7.06], p = 0.003), and TTE (HR 3.05, [95% CI, 1.44-6.45], p = 0.004). Additionally, patients treated with SBRT for metachronous (HR 2.89, [95% CI 0.68-12.30]) and induced metastatic disease (HR 8.96, [95% CI 1.85-43.37]) had significantly shorter TTE compared to synchronous oligometastatic disease (p = 0.006).Using a prospective registry cohort of men with Oligo PCa treated with SBRT, we identify an association of oligometastatic state and the use of concurrent systemic therapy with improved TTRP and TTNT. Further prospective studies are warranted." @default.
• W4387206520 created "2023-09-30" @default.
• W4387206520 creator A5015974298 @default.
• W4387206520 creator A5022694627 @default.
• W4387206520 creator A5036761306 @default.
• W4387206520 creator A5041445209 @default.
• W4387206520 creator A5048562466 @default.
• W4387206520 creator A5053368351 @default.
• W4387206520 creator A5073984828 @default.
• W4387206520 creator A5075890039 @default.
• W4387206520 creator A5076855638 @default.
• W4387206520 creator A5077149161 @default.
• W4387206520 creator A5091434259 @default.
• W4387206520 date "2023-10-01" @default.
• W4387206520 modified "2023-10-17" @default.
• W4387206520 title "Clinical Outcomes with Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: Results from a Prospective Registry Trial" @default.
• W4387206520 doi "https://doi.org/10.1016/j.ijrobp.2023.06.921" @default.
• W4387206520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784680" @default.
• W4387206520 hasPublicationYear "2023" @default.
• W4387206520 type Work @default.
• W4387206520 citedByCount "0" @default.
• W4387206520 crossrefType "journal-article" @default.
• W4387206520 hasAuthorship W4387206520A5015974298 @default.
• W4387206520 hasAuthorship W4387206520A5022694627 @default.
• W4387206520 hasAuthorship W4387206520A5036761306 @default.
• W4387206520 hasAuthorship W4387206520A5041445209 @default.
• W4387206520 hasAuthorship W4387206520A5048562466 @default.
• W4387206520 hasAuthorship W4387206520A5053368351 @default.
• W4387206520 hasAuthorship W4387206520A5073984828 @default.
• W4387206520 hasAuthorship W4387206520A5075890039 @default.
• W4387206520 hasAuthorship W4387206520A5076855638 @default.
• W4387206520 hasAuthorship W4387206520A5077149161 @default.
• W4387206520 hasAuthorship W4387206520A5091434259 @default.
• W4387206520 hasConcept C121608353 @default.
• W4387206520 hasConcept C126322002 @default.
• W4387206520 hasConcept C126838900 @default.
• W4387206520 hasConcept C143998085 @default.
• W4387206520 hasConcept C151730666 @default.
• W4387206520 hasConcept C188816634 @default.
• W4387206520 hasConcept C2776235491 @default.
• W4387206520 hasConcept C2779013556 @default.
• W4387206520 hasConcept C2779343474 @default.
• W4387206520 hasConcept C2780192828 @default.
• W4387206520 hasConcept C2780387249 @default.
• W4387206520 hasConcept C50382708 @default.
• W4387206520 hasConcept C509974204 @default.
• W4387206520 hasConcept C535046627 @default.
• W4387206520 hasConcept C71924100 @default.
• W4387206520 hasConcept C72563966 @default.
• W4387206520 hasConcept C86803240 @default.
• W4387206520 hasConceptScore W4387206520C121608353 @default.
• W4387206520 hasConceptScore W4387206520C126322002 @default.
• W4387206520 hasConceptScore W4387206520C126838900 @default.
• W4387206520 hasConceptScore W4387206520C143998085 @default.
• W4387206520 hasConceptScore W4387206520C151730666 @default.
• W4387206520 hasConceptScore W4387206520C188816634 @default.
• W4387206520 hasConceptScore W4387206520C2776235491 @default.
• W4387206520 hasConceptScore W4387206520C2779013556 @default.
• W4387206520 hasConceptScore W4387206520C2779343474 @default.
• W4387206520 hasConceptScore W4387206520C2780192828 @default.
• W4387206520 hasConceptScore W4387206520C2780387249 @default.
• W4387206520 hasConceptScore W4387206520C50382708 @default.
• W4387206520 hasConceptScore W4387206520C509974204 @default.
• W4387206520 hasConceptScore W4387206520C535046627 @default.
• W4387206520 hasConceptScore W4387206520C71924100 @default.
• W4387206520 hasConceptScore W4387206520C72563966 @default.
• W4387206520 hasConceptScore W4387206520C86803240 @default.
• W4387206520 hasIssue "2" @default.
• W4387206520 hasLocation W43872065201 @default.
• W4387206520 hasLocation W43872065202 @default.
• W4387206520 hasOpenAccess W4387206520 @default.
• W4387206520 hasPrimaryLocation W43872065201 @default.
• W4387206520 hasRelatedWork W1980245127 @default.
• W4387206520 hasRelatedWork W2384708512 @default.
• W4387206520 hasRelatedWork W2603773853 @default.
• W4387206520 hasRelatedWork W2793295628 @default.
• W4387206520 hasRelatedWork W2999207890 @default.
• W4387206520 hasRelatedWork W3048057313 @default.
• W4387206520 hasRelatedWork W335723942 @default.
• W4387206520 hasRelatedWork W4304808194 @default.
• W4387206520 hasRelatedWork W4311192294 @default.
• W4387206520 hasRelatedWork W4320901954 @default.
• W4387206520 hasVolume "117" @default.
• W4387206520 isParatext "false" @default.
• W4387206520 isRetracted "false" @default.
• W4387206520 workType "article" @default.